NorwayNorway

Scientists propose to evaluate overall risk/benefit ratio of transgenic salmon

22.11.2010

Stavanger/Durham – The current safety review of the world’s first transgenic fast-growing salmon is too narrow, according to a Norwegian-US research team (Science, 330 (6007), 1052-1053). Instead of limiting its assessment on health risk and the comparison of the nutritional profile of the GM salmon with conventional salmon that does not grow at low temperatures, the researchers from Stavanger and Duke university recommend to allow the FDA take into account the overall risks and benefits coupled to marketing of the GM salmon. Instead of focusing on the safety of a food taken one portion at a time or whether it was produced through genetic modification or through classic breeding, a more useful approach would be to evaluate whether society is better off overall with the new product on the market than without it, argue the researchers. One possible benefit could be improvement of public health as increased production of transgenic farmed salmon is expected to leads to lower retail prices. „Consumers would have access to a less expensive source of healthy protein and omega-3 fatty acids, which have well-documented health benefits“, according to the researchers. But professor Atle Guttormsen and colleagues also want to add an improved risk assessment to the current review process for transgenic animals. A broader review would also allow a fuller assessment of potential environmental impacts, such as pollution from farmed salmon waste; disease; increased harvesting of the wild fish used to feed farmed salmon. In the future, it would be better to include an evaluation of the overall safety of the new fish into the review process that compares the GM salmon to other protein sources that it might replace, such as beef. Currently, the FDA is carrying out a safety assessment for a GM salmon intended for marketing by the US firm Aquabounty Inc. The AquAdvantage salmon grows significantly faster as normal salmon, due to an inserted growth gene from Pacific chinook salmon (Oncorhynchus tshawytscha) and a switch-on gene from ocean pout (Zoarces americanus), and could become the first genetically modified animal approved for human consumption.

NorwayNorway

05.04.2011

Oslo – Norwegian Algeta ASA has entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform Under the terms of the agreement, Genzyme will provide access to a novel tumour-targeting antibody,...

NorwayNorway

05.04.2011

Trondheim – Norway-based APIM Therapeutics AS has received a follow-up investment from Sarsia Seed, one of its previous investors. APIM focusses on novel drug candidates that potentiate the action of current chemo­therapeutics to...

NorwayNorway

04.11.2010

Oslo – Norwegian diagnostic specialist DiaGenic ASA has raised NOK70m (EUR 8.5m) through the sale of 140 million shares at NOK0.50 per share in a private placement to new and existing investors. DnB NOR Markets acted as manager...

NorwayNorway

03.11.2010

Oslo – The Oslo Cancer Cluster and the Shanghai Institute of Materia Medica (SIMM), have signed a memorandum of understanding aimed at accelerating the development and adoption of new cancer therapies. Overall, the collaboration...

NorwayNorway

18.09.2010

Oslo/Berlin – Algeta is cashing in on its lead product Alpharadin, a targeted alpha-radiopharmaceutical in clinical trials for treating bone metastases in cancer patients. Bayer Schering Pharma has agreed to pay the Norwegian...

NorwayNorway

11.07.2010

Lysaker – Norwegian biopharmaceutical company PCI Biotech Holding ASA has strengthened the company’s equity by a11m (NOK90m) through a share issue of 2.25 million shares with preemptive subscription rights for existing...

NorwayNorway

12.05.2010

Oslo – In Norway, a discussion has begun on how to continue to support biotechnology after the current National Programme for Research in Functional Genomics in Norway (FUGE) comes to a close in 2011. Efforts to draw up a...

Displaying results 11 to 20 out of 92

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/1/article/scientists-propose-to-evaluate-overall-riskbenefit-ratio-of-transgenic-salmon.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR26.6%
  • EPIGENOMICS3.83 EUR23.2%

FLOP

  • ADDEX3.10 CHF-23.8%
  • EVOTEC3.08 EUR-15.8%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 19.09.2014


Current issue

All issues

Product of the week

Products